FDA Approves Mercks Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors
Merck known as MSD outside the United States and Canada announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.









